• NIFTY  
    11,938.30
    (0.14%)
  • SENSEX  
    40,485.64
    ( 0.10%)
  • USDINR  
    71.11
    ( -0.10%)
  • GOLD  
    37,657.00
    ( -0.11%)
  • Hot Pursuit - Detailed News
Sun Pharma sails through the tide after strong Q1 results
13-Aug-19   16:35 Hrs IST

The result was announced during the market hours today, 13 August 2019.

Meanwhile, the S&P BSE Sensex tanked 623.75 points or 1.66% and closed at 36,958.16.

On the BSE, 9.04 lakh shares were traded in the counter so far compared with average daily volumes of 2.91 lakh shares in the past two weeks. The stock hit a high of Rs 444.8 and a low of Rs 420.8 so far during the day. The stock hit a 52-week high of Rs 678.8 on 06 Sep 2018. The stock hit a 52-week low of Rs 350.4 on 13 May 2019.

The company's earnings before interest tax depreciation and amortization (EBITDA) stood at Rs 1881 crore with an EBITDA margin of 22.8% in Q1 June 2019.

The company's R&D investments stood at Rs 422 crores (5.1% of sales) in Q1 June 2019 as compared to Rs. 500 crores (7% of sales) in Q1 June 2018.

Commenting on company's Q1 performance, Dilip Shanghvi, managing director of the company said, “We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance. We are consistently focusing on improving our efficiencies and cost structure to ensure reasonable returns for our generics business. At the same time, we continue our unwavering efforts on building the specialty business and are encouraged by the potential of one of our pre-clinical research molecules which is likely to enter clinical trials next year.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company

Powered by Capital Market - Live News

Useful Links

Back to Top
Attention Investors
Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day.............issued in the interest of investors. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account                                    "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Investors should be cautious of unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.BSE   http://www.bseindia.com/investors/tip-off-registration.aspx?expandable  NSE   https://www.nseindia.com/int_invest/dynacontent/any_portal.htm
All payments to Stock Broker shall be received from the market intermediaries/participants strictly by account payee crossed cheques / demand drafts or by way of direct credit into the bank account through electronic fund transfer, or any other mode permitted by the Reserve Bank of India. Stock Brokers shall not accept cash from their clients either directly or by way of cash deposit to the Bank Account of Stock Broker.
Group Companies Members of : BSE, NSE, MCX, MCX.SX, CDSL, NCDEX, Broking Services, Depository Services, Portfolio Management Services, Member Area IPO Distribution, Insurance Broking
BSE Clearing No.: 911 | SEBI Regn. No.: INZ000177531 (Cash/F&O) | NSE Clearing No.: 11858 | SEBI Regn. No. INZ000177531 (Cash/F&O/CDs) | MCX-SX Clearing No.: 11400 | SEBI Regn. No.: INZ000177531 (CDs) | CDSL DP ID: 30300 | SEBI Regn. No.: IN-DPCDSL-210-2003 | MCX SEBI Reg No.: INZ000032336 | MCX: 10665 | NCDEX: 00254 | NBFC RBI Regn. No.: 13.01851
© Copyright 2018 Ajmera Associates Ltd ( ISO 9001:2015 Certified )
Designed, Developed and Powered By CMOTS Infotech ( ISO 9001:2015 Certified )
Open An Account Today !